How Much Weight Loss Per Week on Wegovy? Insights and Expectations

Last reviewed: July 7, 2026

Last updated: July 7, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Semaglutide, a GLP-1 receptor agonist originally developed for type 2 diabetes, reduces appetite and improves blood sugar control—leading to consistent weight loss in most patients. Clinical trials show an average loss of 15% of body weight over 68 weeks, but weekly progress depends on several individual factors that PlexusDx helps identify through personalized testing.

Typical Weekly Weight Loss Patterns on Semaglutide

Most patients lose between 1 and 2 pounds per week during the first 12 weeks of semaglutide therapy, when the medication is still being titrated upward. This initial phase often includes the most noticeable results because the appetite-suppressing effects are strongest as your body adjusts to the medication. By month four, the rate of weight loss typically plateaus but remains steady at 0.5 to 1 pound per week for many patients. Total body weight reduction averages 15% to 22% by the end of one year, depending on baseline weight and adherence.

Weekly fluctuations are normal and do not indicate failure of the medication. Water retention, hormonal cycles, sodium intake, and exercise timing can all mask fat loss on any given week. PlexusDx recommends tracking monthly or 4-week averages rather than daily weigh-ins to see the true trajectory of your progress. Patience during plateaus is crucial—sustained weight loss over months produces far better long-term health outcomes than rapid drops that often reverse.

What Influences Your Individual Rate of Weight Loss

Your genetic makeup plays a significant role in how much weight you lose on semaglutide and how quickly. The Precision Peptide Genetic Test from PlexusDx analyzes variants in genes like GLP1R (rs6923761), GIPR (rs1800437), and FTO (rs9939609)—each influencing how your body responds to GLP-1 therapy and your baseline metabolism. Patients with favorable genetic variants in the GLP-1 receptor pathway typically experience faster initial weight loss and better appetite suppression than those with less responsive variants. Understanding your genetic profile helps set realistic expectations and informs whether combination therapy might be more effective for your specific biology.

Behavioral and lifestyle factors are equally important as genetics. Calorie intake, exercise frequency, sleep quality, and stress levels all interact with semaglutide's effects on hunger and energy expenditure. Starting weight also matters—patients with higher initial body weight often lose more pounds per week in absolute terms, though the percentage of body weight lost tends to be similar across groups. Concurrent medications, thyroid function, and insulin resistance status further modify how quickly the medication works in each individual.

Monthly Milestones and Long-Term Weight Loss Expectations

Month one typically brings 4 to 8 pounds of weight loss as appetite suppression begins and fluid shifts occur. Months two and three often see the steepest declines, with cumulative losses reaching 12 to 20 pounds by week 12. By month four through month six, the rate usually slows to 1 to 2 pounds per week as your body adapts and reaches a new equilibrium. This deceleration does not mean the medication is failing—it reflects the body's natural adaptation to lower caloric intake and represents genuine fat loss that persists.

Long-term weight loss (six months to two years) averages 15% to 22% of starting body weight in clinical trials, with some patients achieving 25% to 30% reductions. Sustained results require ongoing medication use; weight tends to return if semaglutide is discontinued without lifestyle changes that have become established habits. PlexusDx helps you maintain momentum by providing continuous access to therapy at a flat monthly rate (starting at $189/month), removing cost barriers that often interrupt treatment.

How PlexusDx Personalizes Semaglutide Therapy for Your Goals

Rather than assuming a one-size-fits-all dosing schedule, PlexusDx offers compounded semaglutide from licensed 503A pharmacies with flexible dosing to match your body's response and medical history. Your dose may need to go up—your price won't. Starting at $149 per month, the flat-rate pricing model ensures cost predictability whether you remain on a lower starting dose or advance to a higher therapeutic level. This approach reduces the financial stress that often derails weight loss treatment.

Adding the Precision Peptide Genetic Test ($99 add-on after your first month) reveals your individual genetic predispositions across 14 metabolic pathways and 49 peptides, informing whether semaglutide alone is optimal or whether a dual-compound approach like GLP-Squared (semaglutide plus tirzepatide) might accelerate results. Oral formulations are also available for patients who prefer tablets over injections, starting at $289 per month. PlexusDx accepts HSA and FSA funds and serves all 50 states without requiring insurance or membership fees, making personalized GLP-1 therapy accessible to more people.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $189/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

How much weight should I expect to lose in the first month on semaglutide?

Most patients lose 4 to 8 pounds in the first month as appetite suppression takes hold and initial fluid shifts occur. Individual results vary based on starting weight, calorie intake, and exercise—heavier individuals often see larger absolute losses. PlexusDx's personalized approach helps set realistic month-one goals based on your genetic profile and medical history.

Is 1 to 2 pounds per week on semaglutide normal?

Yes, 1 to 2 pounds per week is typical during the first 12 weeks of semaglutide therapy as the medication is titrated upward. After that, the rate usually drops to 0.5 to 1 pound per week as your body adapts. Clinical trials consistently show this pattern reflects genuine fat loss, not temporary water weight.

What if my weight loss slows or plateaus on semaglutide?

Plateaus are normal and do not mean the medication has stopped working—they reflect your body reaching a new metabolic equilibrium. Reassessing your calorie intake, exercise routine, sleep, and stress can help restart progress. If plateaus persist, PlexusDx offers the Precision Peptide Genetic Test to determine if a dual-compound therapy like GLP-Squared might be more effective for your genetic profile.

Are there side effects that might affect weekly weight loss?

Nausea, constipation, and reduced appetite are common early side effects that usually resolve within 2 to 4 weeks. These effects actually support weight loss by reducing food intake and desire. Severe nausea or vomiting should be reported to your provider—dose adjustments or a switch to oral semaglutide may help. Most patients find side effects manageable and worth the weight loss benefits.

How does the Precision Peptide Genetic Test relate to your GLP-1 pathway?

The test analyzes variants in GLP1R, GIPR, FTO, and MC4R genes that influence appetite regulation and metabolism. Patients with favorable variants typically experience faster initial weight loss and better appetite suppression. PlexusDx uses these insights to recommend whether standard semaglutide, higher doses, or combination therapy will likely work best for your unique biology.

Related Reading

• Wegovy For Weight Loss 2
• Wegovy Weight Loss Pills
• Mounjaro Weight Loss By Week
• Wegovy Vs Zepbound Weight Loss

Pricing and availability current as of July 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.